From the ed­i­tor: Our fi­nal edi­tion of End­points Mar­ket­ingRx

To our Mar­ket­ingRx read­ers —

Last week, we made the de­ci­sion to shut down End­points Mar­ket­ingRx. Over the last year, End­points News has put more re­sources in­to our core bio­phar­ma and health­care cov­er­age, and in­to work where we’re see­ing the most sig­nif­i­cant read­er in­ter­est and sup­port.

We’ll con­tin­ue to cov­er com­mer­cial com­pe­ti­tion and strat­e­gy — in fact, we’re adding re­sources to do so — but as a part of a broad­er sto­ry about how drug prod­ucts are sold. If you haven’t al­ready, I’d en­cour­age you to sign up for our main End­points newslet­ter or our phar­ma re­port cov­er­ing com­mer­cial and reg­u­la­to­ry is­sues. You can click here to up­date your sub­scrip­tion pref­er­ences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER